Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health Inc. is poised for growth as prescriptions for GLP-1 drugs, essential for treating overweight or obesity, have surged by 587% from 2019 to 2024, highlighting a growing market opportunity. The company is advancing its manufacturing efforts to support the upcoming FIH Phase 1 trial while expecting scalable capabilities to enhance as the program develops, indicating strong operational momentum. Positive preliminary data from the REMAIN-1 trial further suggests that GLP-1 PGTx could offer significant improvements in blood glucose management and weight control, positioning Fractyl Health favorably within the competitive landscape of metabolic disease therapies.

Bears say

Fractyl Health Inc. faces a challenging financial outlook primarily due to its high cash burn rate, which may escalate with increased development and commercial programs, coupled with uncertainty regarding the ability to secure sufficient capital for ongoing projects like the Revita and Rejuva platforms. Additionally, the negative implications of impaired GLP-1 function in type 2 diabetes patients could hinder the effectiveness of the company's proposed therapies, especially considering that the observed circulating GLP-1 levels were significantly lower than those associated with existing pharmacological treatments. This scenario raises concerns about the long-term viability and scalability of Fractyl's therapeutic approaches in a competitive market where patient outcomes and treatment tolerability are critical.

GUTS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Strong Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Strong Buy consensus rating as of Jan 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.